A sexual health product developer

Futura Medical plc (LSE:FUM) specialises in the research, development and commercialisation of topically delivered gel formulations for sexual health. Its lead product, Eroxon, is described by the company as "the only topical gel treatment for ED available over the counter". It also has a stronger formulation, Eroxon Intense, and a development candidate, WSD4000, aimed at female sexual health. Futura earns Revenue mainly through commercial partners and royalties rather than selling directly, which means its income depends heavily on how those partners perform.

The fundraise and formal sale process

On 3 September 2026, Futura announced a placing, subscription and retail offer at 0.2 pence per share, alongside the launch of a formal sale process and M&A process under the Takeover Code, which began an offer period. The company said the current market valuation does not adequately reflect the value of its portfolio. Present Value Ltd is acting as M&A adviser, and the process could cover asset sales, licensing deals or a sale of the whole company, with non-binding proposals requested by 2 October 2026.

On 7 September, the retail offer was reported as oversubscribed and increased to £200,000, bringing the total conditional raise to approximately £1.8 million before expenses. The company said net proceeds would extend its cash runway to February 2027 and fund the commercial development of its products and the costs of the sale process. Shareholders approved the resolutions at a general meeting on 23 September, with each receiving roughly 97% support. On 24 September, Futura confirmed that 1,482,327,755 ordinary shares would be in issue following admission, expected on or around 25 September.

Financial performance

Interim results published on 1 September 2026 showed revenue of £1.62 million for the six months to 30 June 2026, compared with £1.00 million a year earlier. However, £1.40 million of this came from a settlement with Haleon, and underlying US Royalty revenue was £0.21 million. The operating loss narrowed to £1.20 million from £6.72 million. Cash was £1.24 million at 30 June and £1.06 million at 31 July. Before the fundraise, the directors said cash was expected to last until approximately October 2026 and disclosed material uncertainties over going concern.

Commercially, Futura ended its US relationship with Haleon and appointed Market Performance Group as its new US partner from 1 September 2026. It received EU market launch clearance for Eroxon Intense, with US FDA clearance expected in the fourth quarter of 2026. In June 2026 it also reported positive home-use testing data for WSD4000.

Risks and what to watch

Even after the raise, Futura's funding runway is limited, so the outcome of the sale process is a key near-term issue. There is no certainty that any offer, licensing deal or asset sale will result. The raise was also heavily dilutive, with new shares representing a majority of the enlarged capital, and warrants were issued to its retail coordinator. Other factors include the performance of the new US partner, the timing of FDA clearance for Eroxon Intense, and a European Patent opposition relating to Eroxon disclosed in July.

Conclusion

Futura raised new Equity and launched a formal sale process because, by its own account, it needed to fund operations beyond October 2026 while exploring whether its sexual health portfolio could achieve a better valuation through a transaction. The proposals due in early October will indicate whether that strategy is gaining traction.